Previous 10 | Next 10 |
Acquisition provides Ligand with the royalty rights to QARZIBA®, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A. QARZIBA is the sixth key asset added to Ligand’s commercial stage portfolio since the b...
CHASKA, Minn., July 01, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced it has reached a cooperation agreemen...
FDA approval increases Ligand’s key commercial stage portfolio to 11 products Ligand is entitled to receive a low single-digit royalty on worldwide net sales of Ohtuvayre Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Verona Pharma plc...
2024-06-18 09:01:00 ET More on Merck Merck & Co., Inc. (MRK) Goldman Sachs 45th Annual Global Healthcare Conference - (Transcript) Dividends And Innovation: Why Merck Is A Healthcare Stock Worth Buying Merck & Co., Inc. (MRK) Investor Event at ASCO 2024 (Tran...
CAPVAXIVE is the sixth FDA-approved product to utilize the Pfenex Expression Technology® platform Ligand is entitled to a royalty on worldwide net sales of CAPVAXIVE Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its collaborator Merck, known as...
2024-05-29 09:55:22 ET Summary Agenus Inc. is developing botensilimab and balstilimab for colorectal cancer, among other oncology indications. The company's timeline for a Biologics License Application filing for BOT/BAL in CRC has been delayed, but an FDA meeting in July could be...
2024-05-24 13:32:38 ET More on Agenus, Ligand Pharma, etc. Ligand Pharmaceuticals Incorporated (LGND) Q1 2024 Earnings Call Transcript Ligand Pharmaceuticals Incorporated 2024 Q1 - Results - Earnings Call Presentation Agenus Inc. (AGEN) Q1 2024 Earnings Call Transcri...
2024-05-20 06:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Amid the rise of the digital innovation space, investors may want to consider biotech stocks to buy. Fundamentally, a rotation into the sector may occur, boding well for the ecosystem befor...
2024-05-07 23:03:10 ET Ligand Pharmaceuticals Incorporated (LGND) Q1 2024 Earnings Conference Call May 07, 2024 04:30 PM ET Company Participants Michael Jeong - Investor Relations Todd Davis - Chief Executive Officer Paul Hadden - Senior Vice President, Investmen...
2024-05-07 16:52:18 ET More on Ligand Pharmaceuticals Ligand Pharmaceuticals Incorporated 2024 Q1 - Results - Earnings Call Presentation Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio Ligand Pharmaceuticals Inc. (LGND) Q4 2023 Earning...
News, Short Squeeze, Breakout and More Instantly...
Ligand Pharmaceuticals Incorporated Company Name:
LGND Stock Symbol:
NASDAQ Market:
Ligand Pharmaceuticals Incorporated Website:
2024-07-30 06:30:09 ET RBC Capital analyst issues OUTPERFORM recommendation for LGND on July 30, 2024 03:16AM ET. LGND was trading at $108.75 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 6 - Buy recomm...
2024-07-30 06:00:04 ET Douglas Miehm from RBC Capital issued a price target of $130.00 for LGND on 2024-07-30 03:16:00. The adjusted price target was set to $130.00. At the time of the announcement, LGND was trading at $108.75. The overall price target consensus is at $1...
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2024 financial results after the close of the U.S. financial markets on Tuesday, August 6, 2024, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial resul...